The hypothesis that efficacy of treatment with monoclonal anti-CD3 is correlated with residual β-cell status is supported by the observation that mice with selleck products better residual β-cell function, as measured
by blood glucose and serum C-peptide levels, were more likely to respond to treatment. It is also supported by earlier studies in which NOD mice that remained diabetic after treatment with monoclonal anti-CD3 F(ab′)2 were restored to full metabolic control with syngeneic islet transplantation.1 These observations are consistent with findings in the Phase 2 BDR study, where increases in endogenous insulin production were most pronounced in otelixizumab-treated subjects with initial residual β-cell function at or above the 50th percentile.14 Overall, our results demonstrate
that low, subimmunogenic doses of monoclonal anti-CD3 F(ab′)2, which result in transient and partial modulation of the CD3–TCR complex, are sufficient to induce high rates of remission in new-onset diabetic NOD mice. While the autoimmune component of type 1 diabetes may be sufficiently resolved following therapy with monoclonal anti-CD3, glycaemic control and functional remission of disease probably depend upon the level of residual β-cell function at the time of treatment. Successfully translating therapy with monoclonal anti-CD3 mAb into a clinical situation may therefore depend not only upon identifying dosing strategies that minimize adverse effects while maximizing efficacy, but also upon identifying the window of treatment www.selleckchem.com/products/AZD6244.html Doxorubicin during which patients are most likely to respond favorably to treatment. The authors thank Vanessa LeFevre and Claire McCall for assistance with manuscript preparation
and Bruce Belanger for performing statistical analyses. Devangi S. Mehta, Rudy A. Christmas and Michael Rosenzweig are employees of Tolerx, Inc. Herman Waldmann is a co-founder of Tolerx, Inc. and is a member of the Board of Directors. “
“Innate lymphoid cells (ILCs) are rare populations of cytokine-producing lymphocytes and are divided into three groups, namely ILC1, ILC2, and ILC3, based on the cytokines that they produce. They comprise less than 1% of lymphocytes in mucosal tissues and express no unique cell surface markers. Therefore, they can only be identified by combinations of multiple cell surface markers and further characterized by cytokine production in vitro. Thus, multicolor flow cytometry is the only reliable method to purify and characterize ILCs. Here we describe the methods for cell preparation, flow cytometric analysis, and purification of murine ILC2 and ILC3. Curr. Protoc. Immunol. 106:3.25.1-3.25.13. © 2014 by John Wiley & Sons, Inc.